NEW YORK — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company developing novel therapies for brain health disorders, announced the pricing of an underwritten public offering of 18,375,000 common shares at a public offering price of $12.25 per share. The company expects to raise approximately $225 million in gross proceeds before deducting underwriting discounts, commissions, and other related expenses.
MindMed has granted underwriters a 30-day option to purchase up to an additional 2,756,250 common shares at the same public offering price, less underwriting discounts and commissions. All of the shares are being offered by the company.
The company said it intends to use the net proceeds from the offering to fund research and development for its product candidates, along with working capital and other general corporate purposes. MindMed may also allocate a portion of the funds toward potential investments or acquisitions that complement its existing portfolio, though no specific plans or agreements are in place.
Jefferies, Leerink Partners, and Evercore ISI are serving as joint bookrunning managers for the offering, while Oppenheimer & Co. and LifeSci Capital are acting as lead managers. The offering is expected to close on or about October 31, 2025, subject to customary closing conditions.
The securities are being offered pursuant to a shelf registration statement on Form S-3 filed with the U.S. Securities and Exchange Commission and made effective upon filing. The offering will be made by means of a prospectus supplement and accompanying prospectus describing the terms of the sale.
MindMed emphasized that this announcement does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor will any sale occur in jurisdictions where such an offer or sale would be unlawful before registration or qualification under local securities laws.
